| 1. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 2. |
- Lopez-Garcia, SC, et al.
(författare)
-
Treatment and long-term outcome in primary distal renal tubular acidosis
- 2019
-
Ingår i: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. - : Oxford University Press (OUP). - 1460-2385. ; 34:6, s. 981-991
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
- Budinova, T., et al.
(författare)
-
Characterization and application of activated carbon produced by H3PO4 and water vapor activation
- 2006
-
Ingår i: Fuel processing technology. - : Elsevier BV. - 0378-3820 .- 1873-7188. ; 87:10, s. 899-905
-
Tidskriftsartikel (refereegranskat)abstract
- Activated carbons have been prepared from woody biomass birch by using various activation procedures: a) treatment with phosphoric acid and pyrolysis at 600 degrees C in inert atmosphere, b) the same as in (a) followed by steam activation at the same temperature and c) treatment with phosphoric acid and direct pyrolysis in a stream of water vapor at 700 degrees C. The surface area and the porosity of the activated carbons were strongly dependent on the treatment after impregnation with H3PO4 (pyrolysis in inert atmosphere, steam pyrolysis or combination of both). Activated carbon, prepared by impregnation with phosphoric acid followed by steam pyrolysis (steam activation) had highly developed porous structure and the largest surface area among all prepared carbons (iodine number 1280 mg/g and BET surface area 1360 m(2)/g). The adsorption capacity of this sample for Hg(II) from aqueous solution was studied in varying treatment conditions: contact time, metal ion concentration and pH. The adsorption followed Langmuir isotherms and the adsorption capacity for Hg(II) at 293 K was 160 mg/g.
|
|
| 4. |
|
|
